Etienne Drouet has been appointed vice president, strategic development at SynteractHCR, a full-service, international CRO. This new position was created to augment company’s oncology and complex trial expertise serving the small and mid-size biopharma segment. Mr. Drouet also joins the senior management team.
 
Mr. Drouet has more than 20 years of experience in executive leadership, program and project management, clinical trial management, and R&D within the contract research and biopharmaceutical industries. He will work to develop company strategy and business models and ensure excellence in operational delivery to clients. He will report directly to chief executive officer Wendel Barr.
 
Mr. Drouet previously served as executive director of global oncology at Premier Research. He also served as a program manager and senior project manager at ICON, held project management positions at AAI Pharma and Cvitkovic and Associés Consultants. He also served as a senior CRA at the Breast Cancer International Research Group, and a research scientist with Sanofi Aventis.
 
“Since we work with smaller and mid-sized companies on complex global trials, integrating his extensive drug development knowledge is key to further improving both the strategic thinking and executional support our clients request,” said Mr. Barr. “We are delighted to have him on board the team.”